GRDN
Guardian Pharmacy·NYSE
--
--(--)
--
--(--)
GRDN fundamentals
During Q4 2025, Guardian Pharmacy (GRDN) reported revenue of 397.62M, a YoY change of 17.44%. Net income was 21.27M, a YoY change of 79.59%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q2,2022 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Apr 1, 2022 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Jun 30, 2022 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 224.08M -- | 253.44M +13.10% | 262.74M -- | 281.07M -- | 275.41M -- | 300.04M +18.39% | 314.39M +19.66% | 338.57M +20.46% | 329.31M +19.57% | 344.33M +14.76% | 377.43M +20.05% | 397.62M +17.44% | 1.45B -- |
Sales and Services Revenue | 224.08M -- | 253.44M +13.10% | 262.74M -- | 281.07M -- | 275.41M -- | 300.04M +18.39% | 314.39M +19.66% | 338.57M +20.46% | 329.31M +19.57% | 344.33M +14.76% | 377.43M +20.05% | 397.62M +17.44% | 1.45B -- |
Cost of Revenue | 177.75M -- | 203.12M +14.27% | 210.55M -- | 226.49M -- | 220.31M -- | 238.75M +17.54% | 253.51M +20.41% | 271.46M +19.86% | 264.96M +20.27% | 276.19M +15.68% | 302.71M +19.40% | 312.11M +14.97% | 1.16B -- |
Cost of Goods and Services | -- -- | 203.12M -- | 210.55M -- | 226.49M -- | 220.31M -- | 238.75M +17.54% | 253.51M +20.41% | 271.46M +19.86% | 264.96M +20.27% | 276.19M +15.68% | 302.71M +19.40% | 312.11M +14.97% | 1.16B -- |
Gross Profit | 46.33M -- | 50.32M +8.62% | 52.19M -- | 54.58M -- | 55.10M -- | 61.29M +21.79% | 60.88M +16.64% | 67.10M +22.95% | 64.35M +16.78% | 68.15M +11.19% | 74.72M +22.74% | 85.50M +27.42% | 292.72M -- |
Operating Expenses | 47.99M -- | 25.03M -47.85% | 58.52M -- | 39.05M -- | 47.17M -- | 44.28M +76.94% | 165.49M +182.78% | 50.35M +28.92% | 51.34M +8.85% | 55.57M +25.48% | 58.37M -64.73% | 54.74M +8.72% | 220.02M -- |
Selling, General and Administrative Expenses | 47.99M -- | 25.03M -47.85% | 58.52M -- | 39.05M -- | 47.17M -- | 44.28M +76.94% | 165.49M +182.78% | 50.35M +28.92% | 51.34M +8.85% | 55.57M +25.48% | 58.37M -64.73% | 54.74M +8.72% | 220.02M -- |
Operating Income | -1.66M -- | 25.30M +1624.71% | -6.33M -- | 15.52M -- | 7.93M -- | 17.00M -32.77% | -104.61M -1552.65% | 16.75M +7.93% | 13.01M +63.94% | 12.58M -26.02% | 16.35M +115.63% | 30.76M +83.60% | 72.70M -- |
Non-Operating Income (Loss) | -501.00K -- | -853.00K -70.26% | -665.00K -- | -965.00K -- | -838.00K -- | -1.16M -35.64% | -1.03M -54.59% | -534.00K +44.66% | 101.00K +112.05% | 7.00K +100.61% | 277.00K +126.95% | 337.00K +163.11% | 722.00K -- |
Other Non-Operating Income (Loss) | -80.00K -- | -151.00K -88.75% | 51.00K -- | -226.00K -- | -73.00K -- | -91.00K +39.74% | -2.00K -103.92% | -113.00K +50.00% | 271.00K +471.23% | 179.00K +296.70% | 437.00K +21950.00% | 500.00K +542.48% | 1.39M -- |
Net Interest Expense | 421.00K -- | 702.00K +66.75% | 716.00K -- | 739.00K -- | 765.00K -- | 1.07M +51.85% | 1.03M +43.30% | 421.00K -43.03% | 170.00K -77.78% | 172.00K -83.86% | 160.00K -84.41% | 163.00K -61.28% | 665.00K -- |
Interest Expense | 421.00K -- | 702.00K +66.75% | 716.00K -- | 739.00K -- | 765.00K -- | 1.07M +51.85% | 1.03M +43.30% | 421.00K -43.03% | 170.00K -77.78% | 172.00K -83.86% | 160.00K -84.41% | 163.00K -61.28% | 665.00K -- |
Pretax Income From Continuing Operations | -2.16M -- | 24.44M +1231.57% | -7.00M -- | 14.56M -- | 7.09M -- | 15.85M -35.16% | -105.64M -1410.24% | 16.22M +11.42% | 13.11M +84.72% | 12.59M -20.58% | 16.63M +115.74% | 31.10M +91.72% | 73.42M -- |
Income Tax Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 176.00K -- | 4.38M -- | 3.83M -- | 3.76M -- | 7.04M +3898.86% | 9.83M +124.52% | 24.46M -- |
Current Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 3.85M -- | -- -- | -- -- | -- -- | 21.39M +454.89% | -- -- |
Deferred Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 701.00K -- | -- -- | -- -- | -- -- | 3.07M +338.52% | -- -- |
Net Income | -2.16M -- | 24.44M +1231.57% | -7.00M -- | 14.56M -- | 7.09M -- | 15.85M -35.16% | -105.82M -1412.75% | 11.84M -18.67% | 9.27M +30.70% | 8.83M -44.30% | 9.59M +109.07% | 21.27M +79.59% | 48.96M -- |
Net Income Attributable to Minority Interests | 3.78M -- | 2.97M -21.38% | 4.29M -- | 2.54M -- | 4.31M -- | 5.22M +75.77% | 6.82M +58.86% | -102.00K -104.01% | -175.00K -104.06% | -203.00K -103.89% | -225.00K -103.30% | 342.00K +435.29% | -261.00K -- |
Net Income Attributable to Owners of the Company | -5.94M -- | 21.47M +461.45% | -11.29M -- | 12.02M -- | 2.79M -- | 10.62M -50.52% | -112.64M -897.70% | 11.94M -0.62% | 9.45M +239.12% | 9.03M -15.00% | 9.82M +108.72% | 20.92M +75.19% | 49.22M -- |
Other Adjustments | -- -- | -- -- | -11.29M -- | 12.02M -- | 2.79M -- | 10.62M -- | 9.35M +182.82% | 0 -100.00% | 0 -100.00% | 0 -100.00% | -- -- | 0 -- | -- -- |
Net Income Attributable to Common Stockholders | -5.94M -- | 21.47M +461.45% | 0 -- | 0 -- | 0 -- | 0 -100.00% | -121.99M -- | 11.94M -- | 9.45M -- | 9.03M -- | 9.82M +108.05% | 20.92M +75.19% | 49.22M -- |
Other Comprehensive Income | 59.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -2.10M -- | -- -- | -- -- | 37.72M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income Attributable to Minority Interests | 3.78M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -5.88M -- | -- -- | -7.00M -- | 14.56M -- | 7.09M -- | 15.85M -- | -- -- | -- -- | 9.27M +30.70% | 8.83M -44.30% | -- -- | -- -- | -- -- |
Basic EPS | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -2 -- | 0.19 -- | 0.15 -- | 0.15 -- | 0.16 +108.00% | 0.33 +73.68% | 0.79 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -2 -- | -- -- | 0.15 -- | 0.15 -- | 0.16 +108.00% | -- -- | -- -- |
Diluted EPS | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -2 -- | -- -- | 0.15 -- | 0.14 -- | 0.15 +107.50% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -2 -- | -- -- | 0.15 -- | 0.14 -- | 0.15 +107.50% | -- -- | -- -- |
You can ask Aime
What is the market's earnings forecast for Guardian Pharmacy next quarter?What were the key takeaways from Guardian Pharmacy’s earnings call?What guidance did Guardian Pharmacy's management provide for the next earnings period?What factors drove the changes in Guardian Pharmacy's revenue and profit?What is Guardian Pharmacy's gross profit margin?What is Guardian Pharmacy's latest dividend and current dividend yield?What does Guardian Pharmacy do and what are its main business segments?Did Guardian Pharmacy beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
